Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports
Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.
Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
